The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association between overall survival and adverse events with lenvatinib treatment in patients with hepatocellular carcinoma (REFLECT).
 
Max W. Sung
Consulting or Advisory Role - Bayer; Eisai
 
Richard S. Finn
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; Genentech/Roche; Lilly; Merck; Novartis; Pfizer
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
 
Shukui Qin
No Relationships to Disclose
 
Kwang-Hyub Han
Research Funding - Bayer; Eisai; Kowa
 
Kenji Ikeda
Honoraria - Dainippon Sumitomo Pharma; Eisai (I)
 
Ann-Lii Cheng
Honoraria - AstraZeneca; Bayer Yakuhin; Eisai; Genentech/Roche
Consulting or Advisory Role - AstraZeneca; Bayer Schering Pharma; Bristol-Myers Squibb; CSR Pharma; Eisai; Genentech/Roche; MSD; Novartis; Ono Pharmaceutical
 
Masatoshi Kudo
Honoraria - Abbvie; Bayer; Bristol-Myers Squibb Japan; EA Pharma; Eisai; Gilead Sciences; Merck Serono; Merck Serono; MSD; Novartis; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; MSD
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst)
 
Ryosuke Tateishi
Consulting or Advisory Role - Bayer; Eisai; Gilead Sciences; Shionogi
Speakers' Bureau - Abbvie; AstraZeneca; Bayer; Bristol-Myers Squibb; Chugai Pharma; Eisai; Fujifilm; GE Healthcare; Gilead Sciences; Medtronic
Research Funding - Kyowa Hakko Kirin
 
Masafumi Ikeda
Honoraria - Abbott Japan; Bayer Yakuhin; Bristol-Myers Squibb Japan; Dainippon Sumitomo Pharma; Eisai; Lilly Japan; Nobelpharma; Novartis; Otsuka; Taiho Pharmaceutical; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - Bayer Yakuhin; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly Japan; MSD; NanoCarrier; Novartis; Shire; Teijin Pharma
Research Funding - ASLAN Pharmaceuticals; AstraZeneca; Baxalta/Shire; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Eisai; Kowa; Kyowa Hakko Kirin; Lilly Japan; Merck Serono; MSD; NanoCarrier; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Takara Bio; Yakult Pharmaceutical
 
Valery Breder
Consulting or Advisory Role - Bayer; BMS Brazil; Boehringer Ingelheim; MSD
Travel, Accommodations, Expenses - Bayer; Boehringer Ingelheim; MSD
 
Kun-Ming Rau
No Relationships to Disclose
 
Yuk Ting Ma
Honoraria - Bayer
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Merck Serono (Inst)
Travel, Accommodations, Expenses - Bayer
 
Angel Alsina
Honoraria - Vital Therapies
Consulting or Advisory Role - Vital Therapies
Speakers' Bureau - Eisai
 
Baek-Yeol Ryoo
No Relationships to Disclose
 
Zhenggang Ren
No Relationships to Disclose
 
Kalgi Mody
Employment - Eisai
 
Corina E. Dutcus
Employment - Eisai
Leadership - Eisai
 
Toshiyuki Tamai
Employment - Eisai
 
Kenichi Saito
Employment - Eisai
 
Fabio Piscaglia
Honoraria - Bayer; Bracco Diagnostics; Eisai
Research Funding - Bayer (Inst)